enGene (NASDAQ:ENGN) Given "Buy" Rating at HC Wainwright

enGene (NASDAQ:ENGN - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $25.00 price target on the stock. HC Wainwright's target price would suggest a potential upside of 377.10% from the company's previous close.

Several other analysts also recently commented on the stock. JMP Securities reiterated a "market outperform" rating and issued a $18.00 price target on shares of enGene in a research report on Monday, December 23rd. UBS Group cut shares of enGene from a "buy" rating to a "neutral" rating and reduced their target price for the company from $34.00 to $7.00 in a report on Friday, February 14th. Piper Sandler assumed coverage on enGene in a report on Tuesday, February 18th. They set an "overweight" rating and a $26.00 price target on the stock. Citizens Jmp upgraded enGene to a "strong-buy" rating in a research report on Monday, November 18th. Finally, Raymond James began coverage on enGene in a research report on Wednesday, November 27th. They set an "outperform" rating and a $23.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $25.89.

enGene Trading Down 0.2 %

Shares of enGene stock opened at $5.24 on Tuesday. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. The company has a fifty day simple moving average of $6.65 and a 200-day simple moving average of $7.16. The stock has a market cap of $267.12 million, a price-to-earnings ratio of -9.03 and a beta of -0.61. enGene has a 12-month low of $4.42 and a 12-month high of $18.40.

Remove Ads

enGene (NASDAQ:ENGN - Get Free Report) last posted its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06. On average, equities analysts forecast that enGene will post -1.56 EPS for the current fiscal year.

Institutional Trading of enGene

Hedge funds have recently modified their holdings of the business. Wolverine Asset Management LLC acquired a new position in enGene during the third quarter worth $37,000. Vontobel Holding Ltd. acquired a new position in shares of enGene during the 4th quarter worth $69,000. Jane Street Group LLC purchased a new position in shares of enGene in the 4th quarter valued at about $93,000. Toronto Dominion Bank purchased a new position in shares of enGene in the 4th quarter valued at about $97,000. Finally, Cubist Systematic Strategies LLC lifted its stake in shares of enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock valued at $102,000 after purchasing an additional 2,080 shares during the period. 64.16% of the stock is owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.